These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38923379)

  • 1. Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    Ayesh H; Suhail S; Ayesh S; Niswender K
    Diabetes Obes Metab; 2024 Sep; 26(9):3801-3809. PubMed ID: 38923379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
    Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
    Rosenstock J; Frías JP; Rodbard HW; Tofé S; Sears E; Huh R; Fernández Landó L; Patel H
    JAMA; 2023 Nov; 330(17):1631-1640. PubMed ID: 37786396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Bajaj HS; Ásbjörnsdóttir B; Bari TJ; Begtrup K; Vilsbøll T; Rosenstock J
    Diabetes Obes Metab; 2024 Sep; 26(9):3810-3820. PubMed ID: 38951942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    Ayesh H; Suhail S; Ayesh S; Niswender K
    Metabol Open; 2024 Jun; 22():100284. PubMed ID: 38699397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
    Qin W; Yang J; Ni Y; Deng C; Ruan Q; Ruan J; Zhou P; Duan K
    Endocrine; 2024 Oct; 86(1):70-84. PubMed ID: 38850440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Shetty S; Suvarna R
    Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
    Frias JP; De Block C; Brown K; Wang H; Thomas MK; Zeytinoglu M; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1745-1753. PubMed ID: 38252888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
    Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
    Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
    Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.